CP-800569

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C26H23ClF7NO3
Molecular Weight	565.908
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCC1=C(Cl)C=CC(OC2=CC=CC(=C2)N(C[C@@H](O)C(F)(F)F)CC3=CC(OC(F)(F)C(F)F)=CC=C3)=C1

InChI

InChIKey=VHSPKQAESIGBIC-HSZRJFAPSA-N

InChI=1S/C26H23ClF7NO3/c1-2-17-12-20(9-10-22(17)27)37-19-7-4-6-18(13-19)35(15-23(36)25(30,31)32)14-16-5-3-8-21(11-16)38-26(33,34)24(28)29/h3-13,23-24,36H,2,14-15H2,1H3/t23-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C26H23ClF7NO3
Molecular Weight	565.908
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Tue Apr 01 16:33:57 GMT 2025` Edited by `admin` on `Tue Apr 01 16:33:57 GMT 2025`
Record UNII	WRB543XRA8
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CP-800569

Code

English

CP800569

Preferred Name

English

(2R)-3-(3-(4-CHLORO-3-ETHYL-PHENOXY)-N-((3-(1,1,2,2-TETRAFLUOROETHOXY)PHENYL)METHYL)ANILINO)-1,1,1-TRIFLUORO-PROPAN-2-OL

Systematic Name

English

2-PROPANOL, 3-((3-(4-CHLORO-3-ETHYLPHENOXY)PHENYL)((3-(1,1,2,2-TETRAFLUOROETHOXY)PHENYL)METHYL)AMINO)-1,1,1-TRIFLUORO-, (2R)-

Systematic Name

English

Code System Code Type Description

PUBCHEM

6918520

Created by admin on Tue Apr 01 16:33:57 GMT 2025 , Edited by admin on Tue Apr 01 16:33:57 GMT 2025

PRIMARY

FDA UNII

WRB543XRA8

Created by admin on Tue Apr 01 16:33:57 GMT 2025 , Edited by admin on Tue Apr 01 16:33:57 GMT 2025

PRIMARY

CAS

263262-73-3

Created by admin on Tue Apr 01 16:33:57 GMT 2025 , Edited by admin on Tue Apr 01 16:33:57 GMT 2025

PRIMARY

Related Record Type Details


					WRB543XRA8

CP-800569

ACTIVE MOIETY

Comments:

A new cholesteryl ester (CE) transfer protein (CETP) inhibitor (CP-800,569) was evaluated. Doses of 30-1,800 mg were administered once daily to healthy subjects for 14 days. Serum CP-800,569 levels increased, and CETP activity decreased, in a dose-related manner. Serum levels of high-density lipoprotein (HDL) increased (by a maximum of 156%), and those of low-density lipoprotein (LDL) decreased (by a maximum of 47%).